

## Denosumab (anti-TNFSF11)

Cat. No.:	HY-P9958A
CAS No.:	615258-40-7
Target:	RANKL/RANK
Pathway:	NF-κB
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

#### Description

Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective against giant cell tumor of bone (GCTB). Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, dense-cell tumor stromal cells [1].

### CUSTOMER VALIDATION

- Regen Ther. 2024 Dec, 27, Pages 181-190.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

[1]. Branstetter DG, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012 Aug 15;18(16):4415-24.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA